AstraZeneca breathes sigh of relief as court blocks US Symbicort genericA US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper competition for the ageing Share XAstraZeneca breathes sigh of relief as court blocks US Symbicort generichttps://pharmaphorum.com/news/astrazeneca-breathes-sigh-of-relief-as-court-blocks-us-symbicort-generic/
Boost for Verona Pharma after trial win with inhaled COPD drugUK-based Verona Pharma has scored a new win with its chronic obstructive pulmonary disease (COPD) drug ensifenitrine, after Share XBoost for Verona Pharma after trial win with inhaled COPD drughttps://pharmaphorum.com/news/verona-pharma-scores-trial-win-with-inhaled-copd-drug/
Health Innovators: David Van Sickle on digital innovation in respiratory medicineIn the first episode of our Health Innovators series, Paul Tunnah speaks to David Van Sickle, CEO of Share XHealth Innovators: David Van Sickle on digital innovation in respiratory medicinehttps://pharmaphorum.com/views-and-analysis/health-innovators-david-van-sickle-on-digitalising-respiratory-medicine/
Verona Pharma to trial lung drug ensifentrine for COVID-19Verona Pharma is to develop its lung drug ensifentrine for patients with COVID-19, joining the legions of drug Share XVerona Pharma to trial lung drug ensifentrine for COVID-19https://pharmaphorum.com/news/verona-pharma-to-develop-lung-drug-for-covid-19/
AZ’s COPD triple therapy approved in the USAstraZeneca’s triple therapy for chronic obstructive pulmonary disease (COPD), Breztri Aerosphere (budesonide+glycopyrrolate+formoterol fumarate), has been approved in the Share XAZ’s COPD triple therapy approved in the UShttps://pharmaphorum.com/news/azs-copd-triple-therapy-approved-in-the-us/
Teva launches digital asthma and COPD rescue inhaler in USTeva has launched new digital inhaler and drug combination in the US, containing built-in sensors that connect to Share XTeva launches digital asthma and COPD rescue inhaler in UShttps://pharmaphorum.com/news/fda-approves-tevas-digital-asthma-and-copd-rescue-inhaler/
Verona says FDA backs plan to take COPD drug into phase 3More than two years after first saying it would take its lead drug into a pivotal trial, Verona Share XVerona says FDA backs plan to take COPD drug into phase 3https://pharmaphorum.com/news/verona-says-fda-backs-plan-to-take-copd-drug-into-phase-3/
FDA rejection scuppers AZ’s hopes of a COPD triple clash with GSKThe FDA has just handed an advantage to GlaxoSmithKline’s triple therapy for chronic obstructive pulmonary disease (COPD) by Share XFDA rejection scuppers AZ’s hopes of a COPD triple clash with GSKhttps://pharmaphorum.com/news/fda-rejection-scuppers-azs-hopes-of-a-copd-triple-clash-with-gsk/
COPD: the world’s biggest neglected disease?We speak to Verona Pharma’s CEO Jan-Anders Karlsson to find out how the company is looking to tackle Share XCOPD: the world’s biggest neglected disease?https://pharmaphorum.com/r-d/views-analysis-r-d/copd-the-worlds-biggest-neglected-disease/
